Latisse Side Effects: An Evidence-Based Reference Guide

Last reviewed: May 2026.

A summary of FDA prescribing information, peer-reviewed clinical literature, and regulatory findings. Sources are listed at the end of this guide.

About This Guide

This page compiles publicly available information about the side effect profile of Latisse (bimatoprost ophthalmic solution 0.03%) and the broader category of over-the-counter lash serums containing prostaglandin analogues. This guide focuses on side effects documented in FDA prescribing information, peer-reviewed ophthalmology literature, and regulatory findings. Every claim is sourced to FDA prescribing documents, peer-reviewed medical literature, manufacturer disclosures, or court records.

Plume Science does not endorse or oppose the use of Latisse. The information below is factual and sourced. For medical decisions about Latisse use, discontinuation, or alternatives, consult a licensed healthcare provider.

Quick Answer

What Is Latisse?

Latisse (bimatoprost ophthalmic solution 0.03%) is the only FDA-approved prescription treatment for eyelash hypotrichosis. It was approved on December 5, 2008, under NDA 022369, and is distributed by Allergan USA, an AbbVie company.¹

The FDA-approved indication, stated verbatim in the prescribing information: "LATISSE is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness."¹

The active ingredient, bimatoprost, is classified by the FDA as a synthetic prostaglandin analogue (specifically, a prostamide F2α analogue).¹ Bimatoprost was originally approved by the FDA in 2001 for the reduction of intraocular pressure in glaucoma patients, marketed as Lumigan. Eyelash growth was first observed as a side effect among glaucoma patients using Lumigan, and Allergan subsequently pursued a separate approval for the cosmetic indication.²

Latisse contains bimatoprost at 0.03% (0.3 mg/mL), preserved with benzalkonium chloride.¹ It is prescription-only in the United States and is not available over the counter.

↑ Back to top

How Latisse Works

The exact mechanism is not fully characterized. The FDA prescribing information states: "Although the precise mechanism of action is unknown, the growth of eyelashes is believed to occur by increasing the percent of hairs in, and the duration of, the anagen or growth phase."¹

Bimatoprost is understood to act on prostaglandin (FP) receptors in hair follicles, inducing resting (telogen) follicles to enter the active growth (anagen) phase, extending the duration of that phase, and stimulating melanogenesis, which produces darker, thicker lashes.³

The same prostaglandin receptor activity that drives lash growth is also responsible for the documented side effect profile. This is the central pharmacological fact of the entire prostaglandin lash serum category.

Documented Side Effects of Latisse

The following side effects are documented in the FDA Full Prescribing Information for Latisse (NDA 022369/S-014, revised August 2021)¹ and supplementary peer-reviewed literature. Frequency data is drawn from the pivotal multicenter, double-masked, randomized, vehicle-controlled study of 278 adult patients.

Eye irritation and itching

Listed among the most frequently reported adverse reactions in the pivotal trial, occurring in less than 4% of patients.¹ Symptoms include burning, stinging, and pruritus at the application site or ocular surface. Generally considered reversible upon discontinuation.

Conjunctival hyperemia (eye redness)

Also listed among the most frequently reported adverse reactions, also occurring in less than 4% of patients in the controlled trial.¹ The mechanism is prostaglandin-mediated vasodilation of conjunctival blood vessels via FP receptor agonism.

Iris pigmentation changes

The FDA prescribing information warns: "Patients should be advised about the potential for increased brown iris pigmentation which is likely to be permanent."¹ The patient labeling adds: "Any darkening of the colored part of the eye known as the iris is NOT expected to reverse and is likely permanent."¹

An important distinction: In the pivotal Latisse clinical trial (lid-margin application route, 278 patients), no cases of iris color change were recorded.⁴ However, the warning is carried in the Latisse label because of data from glaucoma patients using bimatoprost as an eye drop, where iris darkening occurred in 1.5-1.9% of patients.⁴ The lid-margin application route exposes the eye to approximately 5% of the drug compared with direct ophthalmic instillation.⁵

Risk is highest in patients with hazel, green, or mixed-color irises and lowest in blue-eyed patients with fewer melanosomes.⁴⁶

Prostaglandin-associated periorbitopathy (PAP)

This is the most clinically significant side effect documented for the prostaglandin analogue class and the one most relevant to lash serum users. The FDA prescribing information identifies, under Postmarketing Experience: "periorbital and lid changes associated with periorbital fat atrophy and skin tightness resulting in deepening of eyelid sulcus and eyelid ptosis."¹

PAP is a constellation of structural changes to the periorbital region that includes:

• Orbital fat atrophy (loss of fat volume around the eye)
• Deepening of the upper eyelid sulcus
• Upper eyelid ptosis (drooping)
• Enophthalmos (the eye appearing more recessed into the socket)
• Tightening of the periorbital skin
• Inferior scleral show

Filippopoulos et al. first formally described the phenomenon in 2008 in Ophthalmic Plastic and Reconstructive Surgery.⁷ Subsequent MRI-based studies have quantified the orbital fat volume loss directly.⁸

In observational studies of patients using bimatoprost, PAP has been reported in more than 10% of users.⁹ Reversibility data show that most cases show partial to full improvement within 1 to 15 months after discontinuation, but full reversibility is not guaranteed.¹⁰

The American Academy of Ophthalmology's EyeWiki explicitly advises against periorbital fillers, fat grafting, or other cosmetic injectables in patients actively using prostaglandin analogues.¹¹ This is the most important clinical guidance for the medspa and aesthetic-procedure-aware audience: PAP and dermal filler outcomes interact.

Eyelid skin hyperpigmentation

A darkening of the periorbital skin and eyelids, distinct from iris pigmentation. Listed among the most frequently reported adverse reactions in the clinical trial, at less than 4%.¹ The FDA prescribing information states this effect is "expected to reverse after several weeks to months" upon discontinuation.¹ This is the inverse of iris pigmentation changes, which are considered likely permanent.

Dry eye and meibomian gland dysfunction (MGD)

Dry eye symptoms are listed among the most frequently reported adverse reactions in the clinical trial.¹ More significantly, a peer-reviewed study published in Cornea (Mocan et al., 2016) found that meibomian gland dysfunction was present in 92.0% of patients on prostaglandin analogue monotherapy for glaucoma, compared with 58.3% of those on non-PGA medications (P=0.02).¹²

The study concluded: "Long-term administration of PGA is associated with obstructive type of MGD."¹²

MGD is the obstruction or dysfunction of the meibomian glands of the eyelid, which produce the oily layer of the tear film. Clinical consequences include chronic dry eye, blurred vision, and exacerbation of pre-existing ocular surface disease.

Macular edema

The FDA prescribing information includes a formal warning and precaution for macular edema, including cystoid macular edema. The label states: "LATISSE should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema."¹

A 2020 review published in the British Journal of Ophthalmology (Gottlieb et al.) identified 21 case studies reporting cystoid macular edema across post-marketing data for prostaglandin analogue compounds.¹³ For lash-line application, the risk is substantially lower than for direct ocular instillation, but the warning remains on the Latisse label.

Allergic and hypersensitivity reactions

Latisse is contraindicated in patients with hypersensitivity to bimatoprost or any formulation ingredient.¹ The FDA prescribing information identifies hypersensitivity, local allergic reactions, and rash (macular and erythematous) in the postmarketing experience section.¹ The preservative benzalkonium chloride is a known contact sensitizer and may contribute to hypersensitivity reactions.¹

Eyelash changes upon discontinuation

The FDA prescribing information states: "Upon discontinuation of treatment, eyelash growth is expected to return to its pre-treatment level."¹ Some patients report madarosis (temporary lash loss), trichorrhexis (lash breakage), or asymmetric lash growth between eyes during use or after discontinuation.

↑ Back to top

Prostaglandin-Associated Periorbitopathy (PAP): A Deeper Look

Because PAP is the most underdiscussed and clinically significant side effect for lash-serum users, it warrants additional context.

What it is

PAP is a structural change to the orbit and periorbital tissue caused by prostaglandin analogue exposure. The mechanism is believed to involve:

• Apoptosis (programmed cell death) of orbital adipocytes (fat cells)
• Inhibition of adipogenesis
• Levator aponeurosis disinsertion or thinning
• Changes to the periorbital extracellular matrix

The result is a hollowed, deepened, or sunken appearance to the eye area.⁷⁸

When it appears

PAP can become clinically apparent within months of starting a prostaglandin analogue. Some patients are aware of the change; others do not notice until comparing photographs over time, or until an aesthetic provider observes the asymmetry between eyes if only one is treated.

Reversibility

The clinical literature suggests partial to full reversibility in most cases after discontinuation, with improvement typically observed over 1 to 15 months.¹⁰ However, some cases show persistent change, and the degree of reversibility is not predictable in advance.

Implications for aesthetic procedures

The American Academy of Ophthalmology's EyeWiki guidance explicitly cautions against periorbital fillers, fat grafting, blepharoplasty planning, or other periorbital cosmetic procedures in patients actively using prostaglandin analogues.¹¹ The orbital fat atrophy may compromise outcomes, alter anatomy in ways that complicate planning, or progress after a procedure has been performed.

This is the most relevant clinical fact for the cosmetic-medicine-engaged audience: prostaglandin lash serums and elective aesthetic procedures around the eye interact, and the interaction is not in the patient's favor.

↑ Back to top

Higher-Risk Populations

The FDA prescribing information identifies several populations for whom additional caution applies.¹

Pregnancy

Bimatoprost is classified as FDA Pregnancy Category C, meaning animal studies have shown adverse effects and no adequate human studies exist. The prescribing information states: "There are no adequate and well-controlled studies of LATISSE administration in pregnant women."¹ Latisse use is generally not recommended during pregnancy.¹⁴

Breastfeeding

The NIH Drugs and Lactation Database (LactMed) notes that no information is available on the use of bimatoprost during breastfeeding.¹⁵ Caution is generally advised.

Pre-existing ocular surface disease

Patients with dry eye, blepharitis, meibomian gland dysfunction, or other ocular surface conditions may experience exacerbation, given the documented association between prostaglandin analogues and MGD.¹²

Active intraocular inflammation

The FDA prescribing information states: "LATISSE solution should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated."¹

Macular edema risk factors

As noted, aphakic patients, pseudophakic patients with a torn posterior lens capsule, and patients with known macular edema risk factors require caution.¹

Patients planning periorbital cosmetic procedures

Per AAO EyeWiki guidance, patients planning fillers, fat grafting, or blepharoplasty should consider discontinuing prostaglandin analogues well in advance to allow for PAP reversibility assessment.¹¹

Patients with mixed-color irises

Hazel, green, or mixed-color iris patients carry the highest risk for iris pigmentation changes if any systemic absorption occurs.⁴⁶

↑ Back to top

Latisse Compared to Over-the-Counter Lash Serums Containing Prostaglandin Analogues

A common consumer misconception is that over-the-counter lash serums are categorically safer than prescription Latisse because they are sold as cosmetics rather than drugs. The pharmacological reality is more nuanced: many leading OTC lash serums contain different prostaglandin analogue molecules than bimatoprost, but with similar receptor activity and similar documented side effect profiles.

The table below summarizes leading OTC lash serums and their prostaglandin analogue active ingredients, based on each product's published INCI ingredient list and supporting regulatory or litigation records. Class action settlements and regulatory actions are sourced to court records and FDA documents.

Across these brands, total settlements paid to consumers as a result of class action proceedings related to undisclosed prostaglandin analogue ingredients exceed $50 million.^17192122

In 2011, the FDA issued a warning letter to Lifetech Resources LLC, the manufacturer of NeuLash and RapidLash, explicitly stating that isopropyl cloprostenate is a "synthetic prostaglandin analog in the same class of compounds as the active ingredients in FDA-approved drugs" and that the products were therefore unapproved new drugs.²³ The FDA's position is that products containing isopropyl cloprostenate require medical supervision and are not safe for casual use.²⁵

↑ Back to top

International Regulatory Actions on Prostaglandin Analogues in Cosmetics

Canada

Prostaglandins, their derivatives, and their analogues, including bimatoprost, dehydrolatanoprost, and isopropyl cloprostenate, appear on Health Canada's Cosmetic Ingredient Hotlist as prohibited substances when used in cosmetic products.²⁶

European Union

On February 10, 2026, the European Commission's Scientific Committee on Consumer Safety (SCCS) issued a final scientific opinion on three prostaglandin analogue ingredients commonly used in lash and brow serums: methylamido-dihydro-noralfaprostal (MDN), isopropyl cloprostenate (ICP/IPCP), and dechloro dihydroxy difluoro ethylcloprostenolamide (DDDE).

The SCCS conclusion: "none of them can be considered safe for use in cosmetic products intended for the eyelashes."²⁷

The opinion cited the potent pharmacological activity of these compounds, their documented adverse effects, and the absence of a margin of safety adequate to justify cosmetic use in eyelash or eyebrow growth products, even at low concentrations.²⁸

United States

In the United States, isopropyl cloprostenate, methylamido-dihydro-noralfaprostal, and dechloro dihydroxy difluoro ethylcloprostenolamide remain in cosmetic products without formal restriction, despite the FDA's stated position that such products may constitute unapproved drugs.²⁵ Class action litigation has been the primary enforcement mechanism in the U.S. market to date.

↑ Back to top

Prostaglandin-Free Alternatives

The category of prostaglandin-free lash and brow enhancement formulations relies on different active mechanisms, primarily peptide complexes, biotin, panthenol, and conditioning amino acids. These ingredients do not act on prostaglandin receptors and are not associated with prostaglandin-associated periorbitopathy, iris pigmentation, or meibomian gland dysfunction.

Plume Elite Lash & Brow Enhancing Serum

Plume Science's Elite Lash & Brow Enhancing Serum is a prostaglandin-free formulation built around the proprietary Q5 Peptide Complex. It contains no bimatoprost, no isopropyl cloprostenate, no dechloro dihydroxy difluoro ethylcloprostenolamide, and no other prostaglandin analogue. The product does not use prostaglandin analogues and is not associated with the prostaglandin-class adverse-effect profile.

Plume Elite is a cosmetic product. It is not a prescription medication and does not treat hypotrichosis as a medical condition. It is designed to support the appearance of fuller, healthier lashes and brows.

Consumers may consider Plume Elite as a prostaglandin-free option if they are:

• Researching the side effect profile of prostaglandin analogue lash serums
• Planning periorbital aesthetic procedures (filler, blepharoplasty, fat grafting)
• Experiencing dry eye, MGD, or ocular surface sensitivity
• Pregnant, breastfeeding, or planning pregnancy
• Looking for a cosmetic option compatible with sensitive eyes

Explore Plume Elite Lash & Brow Enhancing Serum →

Transitioning from Latisse or a PGA-Based Serum

The lash growth effects of Latisse and other prostaglandin analogue serums are not permanent. The FDA prescribing information states that lash characteristics return to pre-treatment levels upon discontinuation.¹

A practical timeline:

• The eyelash cycle (anagen, catagen, telogen) operates over roughly 4 to 6 months
• After discontinuation, the lashes that grew under prostaglandin influence will shed naturally over this period
• Visible reversion to pre-treatment lash density typically occurs within 6 to 8 weeks of stopping, accelerating thereafter
• For PAP, partial to full improvement typically occurs over 1 to 15 months, though full reversibility is not guaranteed¹⁰

For consumers transitioning off a PGA-based product, a peptide-based prostaglandin-free serum can serve as a bridge that supports the appearance of lashes during and after the cycle reset.

↑ Back to top

Frequently Asked Questions

Is Latisse safe?

Latisse is FDA-approved as a prescription treatment for eyelash hypotrichosis, with safety established for that indication when used as prescribed under physician supervision. The FDA prescribing information documents several side effects, including eye irritation, conjunctival hyperemia, iris pigmentation changes, eyelid skin darkening, and prostaglandin-associated periorbitopathy. Most side effects are reversible upon discontinuation; iris pigmentation changes are considered likely permanent. Safety considerations vary by individual, particularly for patients with pre-existing ocular surface disease, those planning periorbital cosmetic procedures, or those who are pregnant or breastfeeding.¹

What is the most common side effect of Latisse?

The most frequently reported side effects in the pivotal Latisse clinical trial were eye pruritus (itching), conjunctival hyperemia (eye redness), skin hyperpigmentation, ocular irritation, and dry eye, each occurring in less than 4% of patients during the four-month study. Prostaglandin-associated periorbitopathy is the most clinically significant side effect documented in postmarketing surveillance, reported in more than 10% of patients in observational studies of bimatoprost users.¹⁹

Can Latisse change my eye color permanently?

The FDA prescribing information warns that increased brown iris pigmentation is possible and is likely to be permanent. In the pivotal Latisse clinical trial of 278 patients (using the lid-margin application route), no cases of iris color change were recorded. The warning is carried in the label because of data from glaucoma patients using bimatoprost as an eye drop, where iris darkening occurred in 1.5 to 1.9% of patients. Risk is highest in patients with hazel, green, or mixed-color irises.¹⁴

What is prostaglandin-associated periorbitopathy?

Prostaglandin-associated periorbitopathy (PAP) is a constellation of structural changes to the periorbital region caused by prostaglandin analogue exposure. It includes orbital fat atrophy, deepening of the upper eyelid sulcus, upper eyelid drooping (ptosis), and the appearance of the eye becoming more recessed into the socket. PAP has been reported in more than 10% of patients using bimatoprost in observational studies. Most cases show partial to full improvement after discontinuation over 1 to 15 months, but full reversibility is not guaranteed.⁷⁹¹⁰

Are over-the-counter lash serums safer than Latisse?

Not necessarily. Many leading over-the-counter lash serums contain prostaglandin analogue molecules different from bimatoprost (such as isopropyl cloprostenate or dechloro dihydroxy difluoro ethylcloprostenolamide) but with similar receptor activity and similar documented side effect profiles. Class action settlements totaling more than $50 million have been paid across GrandeLASH-MD, Rodan + Fields Lash Boost, RevitaLash Advanced, and Babe Lash, alleging that these products contained drug-class ingredients without adequate consumer disclosure. The FDA issued a warning letter in 2011 stating that isopropyl cloprostenate is a synthetic prostaglandin analogue in the same class as FDA-approved drugs and that products containing it may constitute unapproved drugs.^1719212223

Is it safe to use Latisse during pregnancy?

Latisse is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects, and there are no adequate and well-controlled studies in pregnant women. Use during pregnancy is generally not recommended.¹

What's the difference between Latisse and GrandeLASH-MD?

Latisse is an FDA-approved prescription medication containing bimatoprost 0.03%, indicated for treating eyelash hypotrichosis. GrandeLASH-MD is sold as a cosmetic and contains isopropyl cloprostenate, a different prostaglandin analogue not approved for any therapeutic use. Both products act on the prostaglandin pathway. The manufacturer of GrandeLASH-MD settled a $6.25 million class action in 2024 over claims that consumers were not adequately informed of the prostaglandin analogue ingredient. Isopropyl cloprostenate appears on Health Canada's Cosmetic Ingredient Hotlist as a prohibited substance, and the EU SCCS concluded in February 2026 that the ingredient is not safe for cosmetic use.¹⁷²⁶²⁷

Are there prostaglandin-free alternatives to Latisse?

Yes. Prostaglandin-free lash serums use alternative active ingredients, most commonly peptide complexes, biotin, panthenol, and conditioning amino acids. These ingredients do not act on prostaglandin receptors. Plume Elite Lash & Brow Enhancing Serum is one such formulation, built around the Q5 Peptide Complex; it does not use prostaglandin analogues and is not associated with the prostaglandin-class adverse-effect profile. Prostaglandin-free formulations are cosmetic products, not prescription medications, and do not treat hypotrichosis as a medical condition.

How long does it take for Latisse side effects to appear?

Onset varies by side effect. Eye irritation, conjunctival hyperemia, and pruritus typically appear within the first weeks of use. Eyelid skin hyperpigmentation may appear over several weeks to months. Prostaglandin-associated periorbitopathy may become clinically apparent within months. Iris pigmentation changes may not be noticeable for several months to years and are considered likely permanent.¹

Can I switch from Latisse to a prostaglandin-free serum?

Yes. The FDA prescribing information notes that eyelash characteristics return to pre-treatment levels upon discontinuation of Latisse. The lash cycle resets over 4 to 6 months. During the transition, a prostaglandin-free cosmetic serum can support the appearance of lashes. For decisions about discontinuing a prescription medication, consult a licensed healthcare provider. If you are using a prostaglandin analogue serum and are planning periorbital cosmetic procedures, the AAO advises discontinuation in advance to allow for assessment of any prostaglandin-associated periorbitopathy.¹¹¹

↑ Back to top